Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia

Klimentova, Maria; Shelikhova, Larisa; Ilushina, Maria; Kozlovskaya, Svetlana; Blagov, S.; Popov, Alexander; Kashpor, Svetlana; Fadeeva, Maria; Olshanskaya, Julia; Glushkova, Svetlana; Pershin, Dmitriy; Balashov, Dmitriy; Maschan, Alexei; Maschan, Michael

doi:10.1016/j.jtct.2022.11.022

Cited by 8 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daratumumab and venetoclax combination has been added to a preparative regimen among 20 children with chemorefractory AML who underwent haploidentical HSCT yielding a 2-year event-free survival of 44%. 9 The present report highlights the efficacy of daratumumab as a single agent in inducing short-lived MRD-negative remission in a child with AML with dim CD38 expression.…”

Section: Daratumumab-induced Minimal Residual Disease Negative Remiss...mentioning

confidence: 62%

Daratumumab‐induced minimal residual disease negative remission in CD38 (dim)‐positive pediatric acute myeloid leukemia

Borah

Dinah

Dayal

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Section: Daratumumab-induced Minimal Residual Disease Negative Remiss...mentioning

confidence: 62%

Daratumumab‐induced minimal residual disease negative remission in CD38 (dim)‐positive pediatric acute myeloid leukemia

Borah

Dinah

Dayal

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

“…Daratumumab and venetoclax combination has been added to a preparative regimen among 20 children with chemorefractory acute myeloid leukemia who underwent haploidentical HSCT yielding a 2-year EFS of 44%. 9 Present report highlights efficacy of daratumumab as a single agent in inducing short lived MRD negative remission in a child with dim CD 38 expression.…”

mentioning

confidence: 81%

Daratumumab induced Minimal Residual Disease Negative Remission in CD 38 (dim) Positive Pediatric Acute Myeloid Leukemia

Naithani

Borah

Dinah

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In paediatrics, the tested applications are much fewer but new and exciting results were recently presented establishing venetoclax as an active agent in relapsed or refractory leukaemias, and strongly supporting clinical attempts or trials of BH3 mimetics in other diseases and clinical scenarios in childhood cancers [ 2 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ]. The importance of the paediatric-relevant experience in AML/MDS, which are main areas of development in adults, is linked to its relatively low prevalence and differences from older patients in terms of genetic features and heterogeneity of myeloid neoplasia in children, resulting in difficulties in extrapolating data on BH3 mimetics from adults.…”

Section: Introductionmentioning

confidence: 94%

Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey

et al. 2023

View full text Add to dashboard Cite

Venetoclax, the best established BH3 mimetic, is a practice-changing proapoptotic drug to treat blood cancers in adults. In paediatrics, the data are less but exciting results were recently presented in relapsed or refractory leukaemias demonstrating significant clinical activity. Importantly, the interventions could be potentially molecularly guided as vulnerabilities to BH3 mimetics were reported. Currently, venetoclax is not incorporated into paediatric treatment schedules in Poland but it has been already used in patients that failed conventional therapy in Polish paediatric haemato-oncology departments. The aim of the study was to gather clinical data and correlates of all paediatric patients treated thus far with venetoclax in Poland. We set out to gather this data to help choose the right clinical context for the drug and stimulate further research. The questionnaire regarding the use of venetoclax was sent to all 18 Polish paediatric haemato-oncology centres. The data of November 2022 were gathered and analysed for the diagnoses, triggers for the intervention, treatment schedules, outcomes and molecular associations. We received response from 11 centres, 5 of which administered venetoclax to their patients. Clinical benefit, in most cases consistent with haematologic complete remission (CR), was reported in five patients out of ten, whereas five patients did not show clinical benefit from the intervention. Importantly, patients with CR included subtypes expected to show venetoclax vulnerability, such as poor-prognosis ALL with TCF::HLF fusion. We believe that BH3 mimetics have clinical activity in children and should be available to paediatric haemato-oncology practitioners in well-selected applications.

show abstract

Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia

Cited by 8 publications

References 42 publications

Daratumumab‐induced minimal residual disease negative remission in CD38 (dim)‐positive pediatric acute myeloid leukemia

Daratumumab‐induced minimal residual disease negative remission in CD38 (dim)‐positive pediatric acute myeloid leukemia

Daratumumab induced Minimal Residual Disease Negative Remission in CD 38 (dim) Positive Pediatric Acute Myeloid Leukemia

Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey

Contact Info

Product

Resources

About